학술논문

Update on the Treatment of Ataxia: Medication and Emerging Therapies
Document Type
article
Source
Neurotherapeutics. 17(4)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Brain Disorders
Chronic Pain
Rare Diseases
Pain Research
Neurosciences
Neurodegenerative
Clinical Research
Behavioral and Social Science
Aetiology
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
2.1 Biological and endogenous factors
Neurological
Animals
Anti-Inflammatory Agents
Ataxia
Clinical Trials as Topic
Electric Stimulation Therapy
Exercise Therapy
Fatigue
Humans
Neuroprotective Agents
Pain
Treatment Outcome
Tremor
rehabilitation
clinical trials
neurostimulation
gene therapy
Pharmacology and Pharmaceutical Sciences
Public Health and Health Services
Neurology & Neurosurgery
Pharmacology and pharmaceutical sciences
Biological psychology
Language
Abstract
While rehabilitation therapies always help patients with ataxia, there are currently no FDA-approved treatments for ataxia. Medications are available to treat symptoms that may complicate an ataxic illness, e.g., tremor, myoclonus, dystonia, and rigidity, which are discussed elsewhere in this volume. Spasticity, pain, fatigue, depression, sleep disturbances, cognitive decline, and bowel and bladder dysfunction, if they occur, all have multiple available drugs and therapies for symptomatic use. There is also an extensive literature on off-label uses of various medications to improve imbalance. The pipeline of emerging therapies for symptomatic and possible disease-modifying management of ataxia gives hope that we will soon see the first of many FDA-approved drugs for ataxic illnesses.